Genetic Testing for Hereditary Cancer Syndromes
- Genetic mutations play a role in the development of all cancers. Most of these mutations occur during a person’s lifetime, but some mutations, including those that are associated with hereditary cancer syndromes, can be inherited from a person’s parents.
- Inherited mutations play a major role in the development of about 5 to 10 percent of all cancers.
- The genetic mutations associated with more than 50 hereditary cancer syndromes have been identified, and genetic tests can help tell whether a person from a family with such a syndrome has one of these mutations.
- A genetic counselor, doctor, or other health care professional trained in genetics can help an individual or family understand genetic test results.
What is genetic testing?Genetic testing looks for specific inherited changes (mutations) in a person’s chromosomes, genes, or proteins. Genetic mutations can have harmful, beneficial, neutral (no effect), or uncertain effects on health. Mutations that are harmful may increase a person’s chance, or risk, of developing a disease such as cancer. Overall, inherited mutations are thought to play a role in about 5 to 10 percent of all cancers.
Cancer can sometimes appear to “run in families” even if it is not caused by an inherited mutation. For example, a shared environment or lifestyle, such as tobacco use, can cause similar cancers to develop among family members. However, certain patterns—such as the types of cancer that develop, other non-cancer conditions that are seen, and the ages at which cancer typically develops—may suggest the presence of a hereditary cancer syndrome.
The genetic mutations that cause many of the known hereditary cancer syndromes have been identified, and genetic testing can confirm whether a condition is, indeed, the result of an inherited syndrome. Genetic testing is also done to determine whether family members without obvious illness have inherited the same mutation as a family member who is known to carry a cancer-associated mutation.
Inherited genetic mutations can increase a person’s risk of developing cancer through a variety of mechanisms, depending on the function of the gene. Mutations in genes that control cell growth and the repair of damaged DNA are particularly likely to be associated with increased cancer risk.
Genetic testing of tumor samples can also be performed, but this Fact Sheet does not cover such testing.
Does someone who inherits a cancer-predisposing mutation always get cancer?No. Even if a cancer-predisposing mutation is present in a family, it does not necessarily mean that everyone who inherits the mutation will develop cancer. Several factors influence the outcome in a given person with the mutation.
One factor is the pattern of inheritance of the cancer syndrome. To understand how hereditary cancer syndromes may be inherited, it is helpful to keep in mind that every person has two copies of most genes, with one copy inherited from each parent. Most mutations involved in hereditary cancer syndromes are inherited in one of two main patterns: autosomal dominant and autosomal recessive.
With autosomal dominant inheritance, a single altered copy of the gene is enough to increase a person’s chances of developing cancer. In this case, the parent from whom the mutation was inherited may also show the effects of the gene mutation. The parent may also be referred to as a carrier.
With autosomal recessive inheritance, a person has an increased risk of cancer only if he or she inherits a mutant (altered) copy of the gene from each parent. The parents, who each carry one copy of the altered gene along with a normal (unaltered) copy, do not usually have an increased risk of cancer themselves. However, because they can pass the altered gene to their children, they are called carriers.
A third form of inheritance of cancer-predisposing mutations is X-linked recessive inheritance. Males have a single X chromosome, which they inherit from their mothers, and females have two X chromosomes (one from each parent). A female with a recessive cancer-predisposing mutation on one of her X chromosomes and a normal copy of the gene on her other X chromosome is a carrier but will not have an increased risk of cancer. Her sons, however, will have only the altered copy of the gene and will therefore have an increased risk of cancer.
Even when people have one copy of a dominant cancer-predisposing mutation, two copies of a recessive mutation, or, for males, one copy of an X-linked recessive mutation, they may not develop cancer. Some mutations are “incompletely penetrant,” which means that only some people will show the effects of these mutations. Mutations can also “vary in their expressivity,” which means that the severity of the symptoms may vary from person to person.
What genetic tests are available for cancer risk?More than 50 hereditary cancer syndromes have been described. The majority of these are caused by highly penetrant mutations that are inherited in a dominant fashion. The list below includes some of the more common inherited cancer syndromes for which genetic testing is available, the gene(s) that are mutated in each syndrome, and the cancer types most often associated with these syndromes.
Hereditary breast cancer and ovarian cancer syndrome
- Genes: BRCA1, BRCA2
- Related cancer types: Female breast, ovarian, and other cancers, including prostate, pancreatic, and male breast cancer
- Gene: TP53
- Related cancer types: Breast cancer, soft tissue sarcoma, osteosarcoma (bone cancer), leukemia, brain tumors, adrenocortical carcinoma (cancer of the adrenal glands), and other cancers
- Gene: PTEN
- Related cancer types: Breast, thyroid, endometrial (uterine lining), and other cancers
- Genes: MSH2, MLH1, MSH6, PMS2, EPCAM
- Related cancer types: Colorectal, endometrial, ovarian, renal pelvis, pancreatic, small intestine, liver and biliary tract, stomach, brain, and breast cancers
- Gene: APC
- Related cancer types: Colorectal cancer, multiple non-malignant colon polyps, and both non-cancerous (benign) and cancerous tumors in the small intestine, brain, stomach, bone, skin, and other tissues
- Gene: RB1
- Related cancer types: Eye cancer (cancer of the retina), pinealoma (cancer of the pineal gland), osteosarcoma, melanoma, and soft tissue sarcoma
- Gene: MEN1
- Related cancer types: Pancreatic endocrine tumors and (usually benign) parathyroid and pituitary gland tumors
- Gene: RET
- Related cancer types: Medullary thyroid cancer and pheochromocytoma (benign adrenal gland tumor)
- Gene: VHL
- Related cancer types: Kidney cancer and multiple noncancerous tumors, including pheochromocytoma
Who should consider genetic testing for cancer risk?Many experts recommend that genetic testing for cancer risk should be strongly considered when all three of the following criteria are met:
- The person being tested has a personal or family history that suggests an inherited cancer risk condition
- The test results can be adequately interpreted (that is, they can clearly tell whether a specific genetic change is present or absent)
- The results provide information that will help guide a person’s future medical care
- Cancer that was diagnosed at an unusually young age
- Several different types of cancer that have occurred independently in the same person
- Cancer that has developed in both organs in a set of paired organs, such as both kidneys or both breasts
- Several close blood relatives that have the same type of cancer (for example, a mother, daughter, and sisters with breast cancer)
- Unusual cases of a specific cancer type (for example, breast cancer in a man)
- The presence of birth defects, such as certain noncancerous (benign) skin growths or skeletal abnormalities, that are known to be associated with inherited cancer syndromes
- Being a member of a racial/ethnic group that is known to have an increased chance of having a certain hereditary cancer syndrome and having one or more of the above features as well
Genetic counseling includes a detailed review of the individual’s personal and family medical history related to possible cancer risk. Counseling also includes discussions about such issues as:
- Whether genetic testing is appropriate, which specific test(s) might be used, and the technical accuracy of the test(s)
- The medical implications of a positive or a negative test result (see below)
- The possibility that a test result might not be informative—that is, that the information may not be useful in making health care decisions (see below)
- The psychological risks and benefits of learning one’s genetic test results
- The risk of passing a genetic mutation (if one is present in a parent) to children
Unlike most other medical tests, genetic tests can reveal information not only about the person being tested but also about that person’s relatives. The presence of a harmful genetic mutation in one family member makes it more likely that other blood relatives may also carry the same mutation. Family relationships can be affected when one member of a family discloses genetic test results that may have implications for other family members. Family members may have very different opinions about how useful it is to learn whether they do or do not have a disease-related genetic mutation. Health discussions may get complicated when some family members know their genetic status while other family members do not choose to know their test results. A conversation with genetics professionals may help family members better understand the complicated choices they may face.
How is genetic testing done?Genetic tests are usually requested by a person’s doctor or other health care provider. Although it may be possible to obtain some genetic tests without a health care provider’s order (see Question 9), this approach is not recommended because it does not give the patient the valuable opportunity to discuss this complicated decision with a knowledgeable professional.
Testing is done on a small sample of body fluid or tissue—usually blood, but sometimes saliva, cells from inside the cheek, skin cells, or amniotic fluid (the fluid surrounding a developing fetus).
The sample is then sent to a laboratory that specializes in genetic testing. The laboratory returns the test results to the doctor or genetic counselor who requested the test. In some cases, the laboratory may send the results to the patient directly. It usually takes several weeks or longer to get the test results. Genetic counseling is recommended both before and after genetic testing to make sure that patients have accurate information about what a particular genetic test means for their health and care.
What do the results of genetic testing mean?Genetic testing can have several possible results: positive, negative, true negative, uninformative negative, false negative, variant of unknown significance, or benign polymorphism. These results are described below.
A “positive test result” means that the laboratory found a specific genetic alteration (or mutation) that is associated with a hereditary cancer syndrome. A positive result may:
- Confirm the diagnosis of a hereditary cancer syndrome
- Indicate an increased risk of developing certain cancer(s) in the future
- Show that someone carries a particular genetic change that does not increase their own risk of cancer but that may increase the risk in their children if they also inherit an altered copy from their other parent (that is, if the child inherits two copies of the abnormal gene, one from their mother and one from their father).
- Suggest a need for further testing
- Provide important information that can help other family members make decisions about their own health care.
- Being checked at a younger age or more often for signs of cancer
- Reducing their cancer risk by taking medications or having surgery to remove “at-risk” tissue (These approaches to risk reduction are options for only a few inherited cancer syndromes.)
- Changing personal behaviors (like quitting smoking, getting more exercise, and eating a healthier diet) to reduce the risk of certain cancers
Finally, in patients who have already been diagnosed with cancer, a positive result for a mutation associated with certain hereditary cancer syndromes can influence how the cancer is treated. For example, some hereditary cancer disorders interfere with the body’s ability to repair damage that occurs to cellular DNA. If someone with one of these conditions receives a standard dose of radiation or chemotherapy to treat their cancer, they may experience severe, potentially life-threatening treatment side effects. Knowing about the genetic disorder before treatment begins allows doctors to modify the treatment and reduce the severity of the side effects.
A “negative test result” means that the laboratory did not find the specific alteration that the test was designed to detect. This result is most useful when working with a family in which the specific, disease-causing genetic alteration is already known to be present. In such a case, a negative result can show that the tested family member has not inherited the mutation that is present in their family and that this person therefore does not have the inherited cancer syndrome tested for, does not have an increased genetic risk of developing cancer, or is not a carrier of a mutation that increases cancer risk. Such a test result is called a “true negative.” A true negative result does not mean that there is no cancer risk, but rather that the risk is probably the same as the cancer risk in the general population.
When a person has a strong family history of cancer but the family has not been found to have a known mutation associated with a hereditary cancer syndrome, a negative test result is classified as an “uninformative negative” (that is, does not provide useful information). It is not possible to tell whether someone has a harmful gene mutation that was not detected by the particular test used (a “false negative”) or whether the person truly has no cancer-predisposing genetic alterations in that gene. It is also possible for a person to have a mutation in a gene other than the gene that was tested.
If genetic testing shows a change that has not been previously associated with cancer in other people, the person’s test result may report “variant of unknown significance,” or VUS. This result may be interpreted as “ambiguous” (uncertain), which is to say that the information does not help in making health care decisions.
If the test reveals a genetic change that is common in the general population among people without cancer, the change is called a polymorphism. Everyone has commonly occurring genetic variations (polymorphisms) that are not associated with any increased risk of disease.
Who can help people understand their test results?A genetic counselor, doctor, or other health care professional trained in genetics can help an individual or family understand their test results. Such counseling may include discussing recommendations for preventive care and screening with the patient, referring the patient to support groups and other information resources, and providing emotional support to the person receiving the results.
In some cases, a genetic counselor or doctor may recommend that other family members consider being tested for specific gene changes that indicate an increased risk of cancer. The decision to test other family members is complicated. It requires a careful evaluation of family history and other factors as well as advice from a genetic counselor or other professional trained in genetics. In general, physicians rely on the family member who has been tested to share the genetic information with their relatives so that family members will know that a genetic condition has been identified in their family. Then, each family member will need to make their own decision regarding whether or not to be tested themselves.
Who has access to a person’s genetic test results?Medical test results are normally included in a person’s medical records, particularly if a doctor or other health care provider has ordered the test or has been consulted about the test results. Therefore, people considering genetic testing must understand that their results may become known to other people or organizations that have legitimate, legal access to their medical records, such as their insurance company or employer, if their employer provides the patient’s health insurance as a benefit.
However, legal protections are in place to prevent genetic discrimination, which would occur if insurance companies or employers were to treat people differently because they have a gene mutation that increases their risk of a disease such as cancer or because they have a strong family history of a disease such as cancer.
In 2008, the Genetic Information Nondiscrimination Act (GINA) became federal law for all U.S. residents. GINA prohibits discrimination based on genetic information in determining health insurance eligibility or rates and suitability for employment. However, GINA does not cover members of the military, and it does not apply to life insurance, disability insurance, or long-term care insurance. Some states have additional genetic nondiscrimination legislation that addresses the possibility of discrimination in those contexts.
In addition, because a person’s genetic information is considered one kind of health information, it is covered by the Privacy Rule of the Health Information Portability and Accountability Act (HIPAA) of 1996. The Privacy Rule requires that health care providers and others with medical record access protect the privacy of health information, sets limits on the use and release of health records, and empowers people to control certain uses and sharing of their health-related information. Many states also have laws to protect patient privacy and limit the release of genetic and other health information. The National Human Genome Research Institute Genetic Discrimination page includes links to more information about GINA, HIPAA, and other legislation related to genetic discrimination in insurance or employment.
What are at-home or direct-to-consumer genetic tests?Some companies offer at-home genetic testing, also known as direct-to-consumer (DTC) genetic testing. People collect a tissue sample themselves and submit the sample through the mail. They learn about the test results online, by mail, or over the phone. DTC genetic testing is often done without a doctor’s order or guidance from a doctor or genetic counselor before the test. Some states in the United States do not allow DTC genetic testing.
Whereas the genetic testing for cancer that is typically ordered by a doctor involves testing for rare major hereditary cancer syndromes, most DTC genetic testing for cancer risk involves the analysis of common inherited genetic variants, called single-nucleotide polymorphisms, that have been shown to be statistically associated with a particular type of cancer. Each individual variant is generally associated with only a minor increase in risk, and even when added together all the known variants for a particular cancer type account for only a small portion of a person’s risk of that cancer. Although the identification and study of such variants is an active area of research, genetic tests based on these variants have not yet been found to help patients and their care providers make health care decisions and, therefore, they are not a part of recommended clinical practice.
Even when people have DTC genetic tests for known mutations in genes associated with hereditary cancer syndrome, there are potential risks and drawbacks to the use of DTC testing. In particular, without guidance about genetic test results from an informed, genetically knowledgeable health care provider, people may experience unneeded anxiety or false reassurance, or they may make important decisions about medical treatment or care based on incomplete information.
Also, although some people may view DTC genetic testing as a way to ensure the privacy of their genetic test results, companies that offer DTC genetic testing do not always tell the consumer the details of their privacy policies. In addition, if people consult their doctor or other health care provider about the test results obtained from a DTC testing vendor, the results may become part of the patient’s medical record anyway. Also, companies that provide DTC testing may not be subject to current state and federal privacy laws and regulations. It is generally recommended that people considering DTC genetic testing make sure that they have chosen a reputable company.
The U.S. Federal Trade Commission (FTC) has a fact sheet about at-home genetic tests which offers advice for people who are considering such a test. As part of its mission, the FTC investigates complaints about false or misleading health claims in advertisements.
The American Society of Human Genetics, a membership organization of genetics professionals, has issued a statement about DTC genetic tests that recommends transparency in such testing, provider education about the testing, and the development of appropriate regulations to ensure test and laboratory quality.
How are genetic tests regulated?U.S. laboratories that perform health-related testing, including genetic testing, are regulated under the Clinical Laboratory Improvement Amendments (CLIA) program. Laboratories that are certified under CLIA are required to meet federal standards for quality, accuracy, and reliability of tests. All laboratories that do genetic testing and share results must be CLIA certified. However, CLIA certification only indicates that appropriate laboratory quality control standards are being followed; it does not guarantee that a genetic test being done by a laboratory is medically useful.
The Centers for Medicare and Medicaid Services has more information about CLIA programs. The National Library of Medicine also has information about how genetic testing is regulated and how to judge the quality of a genetic test. This information is available in the Genetics Home Reference.
What research is being done to improve genetic testing for cancer?Research to find newer and better ways of detecting, treating, and preventing cancer in people who carry genetic mutations that increase the risk of certain cancers is ongoing. Scientists are also doing studies to find additional genetic changes that can increase a person’s risk of cancer.
NCI’s Cancer Genetic Markers of Susceptibility project, launched in 2005, is identifying common inherited genetic variations that are associated with an increased risk of breast cancer, prostate cancer, and other cancer types. This research may lead to new ways to prevent, diagnose, and treat cancer. However, none of the genetic variants identified through that type of research has yet proven useful for clinical management, so this remains a research effort.
NCI also funds the Cancer Genetics Network . This network is a resource for researchers studying inherited cancer risk, the integration of this information into medical practice, and behavioral, ethical, and public health issues associated with human genetics.
Additional NCI research is focused on improving genetic counseling methods and outcomes, the risks and benefits of at-home genetic testing, and the effects of advertising of these tests on patients, providers, and the health care system. Researchers are also working to improve the laboratory methods available for genetic testing.
- Garber J, Offit K. Hereditary cancer predisposition syndromes. Journal of Clinical Oncology 2005; 23(2):276–292.
- Hudson K, Javitt G, Burke W, et al. ASHG statement on direct-to-consumer genetic testing in the United States. American Journal of Human Genetics 2007; 81(3):635–637. [PMC Article]
- Lindor NM, McMaster ML, Lindor CJ, Greene MH. Concise handbook of familial cancer susceptibility syndromes—second edition. Journal of the National Cancer Institute Monographs 2008; 38:1–93.
- Riley BD, Culver JO, Skrzynia C, et al. Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors. Journal of Genetic Counseling 2012; 21(2):151–161.
- Robson M, Storm C, Weitzel J, et al. American Society of Clinical Oncology Policy Statement update: Genetic and genomic testing for cancer susceptibility. Journal of Clinical Oncology 2010; 28(5):893–901.
- Spencer DH, Lockwood C, Topol E, et al. Direct-to-consumer genetic testing: reliable or risky? Clinical Chemistry 2011; 57(12): 1641–1644.
This text may be reproduced or reused freely. Please credit the National Cancer Institute as the source. Any graphics may be owned by the artist or publisher who created them, and permission may be needed for their reuse.